Study wrapper · #149
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Editor's note
This is a post hoc analysis of two Phase 2 trials of survodutide, a dual glucagon/GLP-1 receptor agonist; semaglutide appears only as an active comparator in one arm, not as the study's focus. Researchers reported that in participants with type 2 diabetes (n=413, 16 weeks) survodutide was associated with rapid increases in a beta-cell function index (HOMA-beta) and decreases in insulin resistance (HOMA-IR), glucagon and fasting glucose, while in a normoglycemic overweight/obesity trial (n=387, 46 weeks) it reduced HOMA-IR, glucagon, C-peptide and fasting insulin and raised adiponectin. Notably, weight change explained the largest share of variability in insulin/HOMA-IR but not the other markers, suggesting effects partly independent of weight loss. Caveats: post hoc analyses are hypothesis-generating, HOMA indices are surrogates, durability after stopping is unknown, and this is survodutide, not semaglutide, evidence. Weight it as an early mechanistic signal for a different investigational agent.
Plain-language abstract
This analysis re-examined data from two mid-stage trials of survodutide, an experimental drug that activates two hormone receptors (glucagon and GLP-1). Semaglutide was included only as a comparison treatment in one of the trials. In the first trial, 413 people with type 2 diabetes on metformin received survodutide, placebo, or semaglutide for 16 weeks; in the second, 387 people with overweight or obesity and normal blood sugar received survodutide or placebo for 46 weeks. The researchers looked at markers of how well the insulin-producing cells work and how sensitive the body is to insulin. In the diabetes trial, survodutide was linked to better beta-cell markers and lower insulin resistance, glucagon, and fasting blood sugar. In the second trial it improved insulin sensitivity and related markers. Weight loss explained much of the change in insulin resistance but not the other improvements, suggesting some benefits beyond weight loss. The authors note these are exploratory findings and that it is unknown whether the benefits last after stopping.